TP53 and hepatocellular carcinoma: Additionally, significantly mutated gene analysis performed in the TCGA-LIHC cohort revealed that patients with high HCCEvoSig scores had a significantly higher probability of TP53 mutations (50% in high vs 13% in low HCCEvoSig risk group, p = 1.00 × 10−12; Supplementary Figure S6A), which was further confirmed in three independent validation cohorts (Supplementary Figure S6B-D; ICGC-LIRI-JP, CHCC-HBV and Mongolian-HCC cohorts).